Alzheimer Disease

Nymox pursuing new approaches to Alzheimer disease

Published in Health Business Week, December 22nd, 2006

Nymox Pharmaceutical Corporation (NYMX) is taking innovative approaches to the diagnosis and treatment of Alzheimer's disease.

It is widely recognized that new methods of treating and diagnosing Alzheimer disease are urgently needed in the face of an impending world-wide epidemic of Alzheimer disease. Currently, an estimated 4.5 million Americans and more than 15 million people around the world suffer from the disease. By 2050, this number is expected to triple, creating enormous burdens on health-care systems, care-givers and communities.

Nymox's AD drug development programs focus on novel proprietary approaches to the diagnosis and treatment of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Business Week

Source: Health Business Week (2006-12-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry